Navigation Links
Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress

BASEL, Switzerland, May 21, 2007 - Results from phase III clinical trials and further human pharmacology studies were presented at the 16th Congress of the European Academy of Dermatology and Venereology (EADV). These data highlighted the efficacy and safety profile of alitretinoin as a potential once daily oral treatment for patients with severe refractory chronic hand eczema.

Currently, no approved treatment exists for severe Chronic Hand Eczema (CHE) refractory or unresponsive to topical therapy. This debilitating disease can cause significant pain and functional impairment of the hands as well as considerable psychological, social and occupational impact on patients' lives. The data presented at this meeting will form part of the regulatory submissions later this year and show the potential for alitretinoin to become the first product available to treat an estimated one million patients in North America and Europe.

Eight posters on alitretinoin presented in the main conference and four oral presentations in a company sponsored satellite symposium highlighted alitretinoin as a potential treatment for severe refractory CHE.

Positive efficacy and safety data on alitretinoin were reported in posters from the pivotal BACH trial (poster number 275), the re-treatment study (280) and an open-label safety study (281). Five further posters covered aspects of the pharmacology of alitretinoin (286, 287, 288, 289 and 290).

Previously reported results for the phase III BACH study (275) confirm the efficacy and tolerability of oral alitretinoin for the treatment of CHE in patients refractory to topical corticosteroids. Once daily alitretinoin resulted in response of 48% of the patients who were treated with 30mg per day for up to six months. Response rate and time to response were dose dependent with a faster response seen with the higher dose. Alitretinoin was generally well tolerated in these
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
6. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
7. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
8. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
9. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
10. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
11. Studies Show Efficacy and Safety of Alexions Soliris in Broad Population of PNH Patients
Post Your Comments:
(Date:11/30/2008)... , CHICAGO, Dec. 1 O...cerebral blood flow and a greater number of small ...presented today at the annual meeting of the Radio... The study, conducted at the University of Nort... compare brain scans of older adults who exercise ...
(Date:11/28/2008)...APOLIS, Nov. 28 Eli Lill...pplemental New Drug Application (sNDA) from,the U...a(R) (duloxetine HCl),for the management of chron...n,the first half of 2009, adding data from a rece...hritis pain of the knee. , The decision doe...
(Date:11/26/2008)...sed information density, automation and intelligen...n ultrasound to an all new level , , CHICAG...s Healthcare ( www.siemens.com/healthcare ) hi...ume Scanner (ABVS)(1), the world,s first multi-us...he 94th Scientific Assembly and Annual Meeting of ...
(Date:11/25/2008)...ILLE, Ky., Nov. 25 Klei...eons performed the fifth U.S. hand transplant on M... Louisville,s Jewish Hospital Hand Care Center on ...an around noon and was completed shortly after 9 p...ttp://www.newscom.com/cgi-bin/prnh/20081125/DC4855...
Breaking Medicine Technology:Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3VIE Healthcare Expands Its Operations in the Midwest and Obtains First Local Client 14637 1VIE Healthcare Expands Its Operations in the Midwest and Obtains First Local Client 14637 2CVS Caremark Corp to Pay 2436 7 Million to U S 23 States 26 D C to Settle Medicaid Prescription Drug Fraud Allegations 14636 1CVS Caremark Corp to Pay 2436 7 Million to U S 23 States 26 D C to Settle Medicaid Prescription Drug Fraud Allegations 14636 2AUDIO from Medialink and Kelloggs 3A A Blissful Way to Recommit to Your Resolution 14634 1New Foam Treatment for Varicose Veins 14633 1New Foam Treatment for Varicose Veins 14633 2
...re/ -- Accera, Inc.,today is presenting data from ...trial of AC-1202 (Ketasyn) in Alzheimer,s disease ...l Conference on,Prevention of Dementia in Washingt...linical and preclinical studies, AC-1202 was,shown...y and,cognition of subjects of a particular pharma...
...2007 - Critical,Therapeutics, Inc. (Nasdaq: CRTX) ...otal Phase III clinical trial of ZYFLO CR(TM),(zil...ssue of the,Journal of Asthma. ZYFLO CR was approv...on May 30, 2007. Critical Therapeutics,together w...cts to,begin marketing ZYFLO CR in the U.S. in the...
Other Medicine Technology:Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 2Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 3Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5
(Date:12/2/2008)... Trials of tasimelteon show it could aid shift wo...ESDAY, Dec. 2 (HealthDay News) -- The experimental...aused by jet lag or night shifts, according to the...e II study included 39 people randomly assigned to... mg of tasimelteon, or a placebo. They were monito...
(Date:12/2/2008)... ORLANDO, Fla., Dec. 2 MEDai, Inc...care solutions provider, has added a new module,t...ons. The new stand-alone,module monitors a popul...delines and alerts stakeholders when there has bee...e Risk Navigator Guidelines(TM) provides,real-tim...
(Date:12/2/2008)... -Survey Reveals Nearly Half Have Skipped Medical...., Dec. 2 A new survey ...urce Center (NWHRC) highlights another troubling a...have failed to seek health care for themselves or ...ate that many women say their health has gotten wo...
(Date:12/2/2008)... MALVERN, Pa., Dec. 2 Arlington M...ket intelligence for the pharmaceutical and diagno...Janssen Pharmaceuticals, Levaquin,is the preferre... general,medical-surgical hospitals in the United...lung, sinus, skin and urinary tract infections cau...
Breaking Medicine News(10 mins):Health News:Drug Effective for Temporary Sleep Disruptions 2Health News:MEDai Evidence-Based Guideline Reporting Provides Decision Support at Point of Care 2Health News:Rising Health Costs Prompt Women to Neglect Health 2Health News:Rising Health Costs Prompt Women to Neglect Health 3Health News:Rising Health Costs Prompt Women to Neglect Health 4Health News:Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States 2
... Holtgrave, PhD, an expert on HIV prevention at th... a targeted campaign of testing and counseling aim... more effective than the mass patient screening pr...rol and Prevention (CDC). Holtgraves study is the...
...issue of CHEST, reports that children receiving an...r risk for developing asthma by age 7 than those ...oubled in children receiving antibiotics for nonre...ldren who received multiple antibiotic courses and...
... the issue of Neurology, the scientific journal of...easily distressed and have more negative emotions ...ore easygoing people. In the study, those who mos...ch as depression and anxiety were 40 percent more ...
...es re-sat their examinations Monday after a cheati...lts, an official said Monday . Lawyers hired by th...hools (CGFNS) acted as observers at examination ce...vao. Labour Secretary Arturo Brion said the gradu...
Other Medicine News:Health News:Targeted HIV Testing An Effective Way to Screen HIV Patients 2Health News:Antibiotic Use in Infants may Lead to Asthma. 2Health News:Pessimists may Develop More Memory Problems 2Health News:Philippine Nurses Re-sit Scandal-tainted Exams 2
Cold light source single outlet.
Cold light source triple outlet.
Cold light source single outlet.
The 9100 is a truly affordable 100 Watt xenon light source providing accurate color and brightness. This xenon light source is ideal for surgery centers, evaluations or general office use.
Medicine Products: